Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 29;145(22):2666-2670.
doi: 10.1182/blood.2024027034.

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

Nora M Gibson  1 , Eugene Khandros  2 , Caitlin W Elgarten  1 , Elizabeth Worster  1 , Dimitrios S Monos  3   4 , Alexis A Thompson  2 , Janet L Kwiatkowski  2 , Timothy S Olson  1
Affiliations

Impact of HLA alloimmunization in gene-modified autologous stem cell transplant for transfusion-dependent thalassemia

Nora M Gibson et al. Blood. .

Abstract

We report our single-center experience demonstrating that HLA class I alloimmunization predicts longer time to platelet engraftment, increased bleeding complications, and higher transfusion requirements in patients undergoing gene-modified hematopoietic stem cell transplant for transfusion-dependent β thalassemia.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: E.K., C.W.E., A.A.T., J.L.K., and T.S.O. conducted research with bluebird bio and Vertex Pharmaceuticals. A.A.T., J.L.K., and T.S.O. consulted for bluebird bio and Vertex Pharmaceuticals. J.L.K. consulted for Editas. D.S.M. is chair of the scientific advisory board of Omixon, and receives royalties and owns options in Omixon. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Platelet engraftment and transfusion requirements in gene therapy and MRD alloSCT. N, no; Y, yes.
See this image and copyright information in PMC

Comment in

References

    1. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260. - PubMed
    1. Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-β(0)/β(0) genotype β-thalassemia. N Engl J Med. 2022;386(5):415–427. - PubMed
    1. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479–1493. - PubMed
    1. Panch SR, Guo L, Vassallo R. Platelet transfusion refractoriness due to HLA alloimmunization: evolving paradigms in mechanisms and management. Blood Rev. 2023;62 - PubMed
    1. Lo SC, Chang JS, Lin SW, Lin DT. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients. Transfusion. 2005;45(5):761–765. - PubMed